143 related articles for article (PubMed ID: 25261231)
1. A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC).
Hu X; Han B; Gu A; Zhang Y; Jiao SC; Wang CL; He J; Jia X; Zhang L; Peng J; Wu M; Ying K; Wang J; Ma K; Zhang S; You C; Tan F; Wang Y; Ding L; Sun Y
Lung Cancer; 2014 Nov; 86(2):207-12. PubMed ID: 25261231
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of icotinib in advanced lung squamous cell carcinoma.
Liang S; Xu Y; Tan F; Ding L; Ma Y; Wang M
Cancer Med; 2018 Sep; 7(9):4456-4466. PubMed ID: 30109777
[TBL] [Abstract][Full Text] [Related]
3. Icotinib With Concurrent Radiotherapy vs Radiotherapy Alone in Older Adults With Unresectable Esophageal Squamous Cell Carcinoma: A Phase II Randomized Clinical Trial.
Luo H; Jiang W; Ma L; Chen P; Fang M; Ding L; Hua Y; Du D; Jing Z; Xie R; Song Y; Wang J; Zhou R; Tian Z; Wu S
JAMA Netw Open; 2020 Oct; 3(10):e2019440. PubMed ID: 33026449
[TBL] [Abstract][Full Text] [Related]
4. [Prognostic value of skeletal muscle measured by CT at the T4 level in advanced EGFR-positive non-small cell lung cancer patients treated with ecotinib].
Xia H; Tan XY; Lu XT; Wang SF; Cao YQ; Luo P; Song SW; Guo MF; Yang L; Jin Y
Zhonghua Yi Xue Za Zhi; 2024 May; 104(18):1590-1600. PubMed ID: 38742346
[No Abstract] [Full Text] [Related]
5. A phase II study of single-agent gefitinib as first-line therapy in patients with stage IV non-small-cell lung cancer.
Suzuki R; Hasegawa Y; Baba K; Saka H; Saito H; Taniguchi H; Yamamoto M; Matsumoto S; Kato K; Oishi T; Imaizumi K; Shimokata K
Br J Cancer; 2006 Jun; 94(11):1599-603. PubMed ID: 16670714
[TBL] [Abstract][Full Text] [Related]
6. A Phase II Study of Gefitinib With Concurrent Thoracic Radiotherapy in Patients With Unresectable, Stage III Non-small-cell Lung Cancer Harboring EGFR Mutations (WJOG6911L).
Akamatsu H; Harada H; Tokunaga S; Yoshimura N; Ikeda H; Oizumi S; Sugimoto N; Takano T; Murakami H; Nishimura Y; Yamamoto N; Nakagawa K
Clin Lung Cancer; 2019 Jan; 20(1):e25-e27. PubMed ID: 30266586
[TBL] [Abstract][Full Text] [Related]
7. Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer.
Cho BC; Chiu CH; Massarelli E; Buchschacher GL; Goto K; Overbeck TR; Loong HHF; Chee CE; Garrido P; Dong X; Fan Y; Lu S; Schwemmers S; Bordogna W; Zeuner H; Osborne S; John T
Lung Cancer; 2024 Feb; 188():107442. PubMed ID: 38171156
[TBL] [Abstract][Full Text] [Related]
8. Icotinib as Adjuvant Treatment for Stage II-IIIA Lung Adenocarcinoma Patients with EGFR Mutation (ICWIP Study): Study Protocol for a Randomised Controlled Trial.
Liu YT; Hao XZ; Liu DR; Cheng G; Zhang SC; Xiao WH; Hu Y; Liu JF; He M; Ding CM; Zhang L; Wang J; Li H; Dong GL; Zhi XY; Li J; Shi YK
Cancer Manag Res; 2020; 12():4633-4643. PubMed ID: 32606956
[TBL] [Abstract][Full Text] [Related]
9. Patient comprehension and attitudes toward maintenance chemotherapy for lung cancer.
Gerber DE; Hamann HA; Rasco DW; Woodruff S; Lee SJ
Patient Educ Couns; 2012 Oct; 89(1):102-8. PubMed ID: 22632736
[TBL] [Abstract][Full Text] [Related]
10. The Role of Baseline Sarcopenia Index in Predicting Chemotherapy-Induced Undesirable Effects and Mortality in Older People with Stage III or IV Non-Small Cell Lung Cancer.
Chen X; Hou L; Shen Y; Wu X; Dong B; Hao Q
J Nutr Health Aging; 2021; 25(7):878-882. PubMed ID: 34409965
[TBL] [Abstract][Full Text] [Related]
11. Is cryoablation still suitable for advanced non-small cell lung cancer after failure of first-line chemotherapy? A multicenter, prospective, randomized-controlled trial of eighty-seven patients.
Chen Y; Fang X; Wang D; Li Q; Zhang K; Li Y; Li J; Pang H; Cheng Z; Zhang C; Zhang C; Yang W; Zhu B; Fan H; Han C; An Y; Zhang L; Luo B; Zhang S; Lu T; Meng Y; Jiao Q; Tang H; Zhou T; Hu K
Cryobiology; 2024 Jun; 115():104864. PubMed ID: 38387752
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of icotinib in adult patients with neurofibromatosis type 2 and progressive vestibular schwannoma.
Zhao F; Li SW; Zhang S; Li P; Zhao C; Zhao XB; Wang CH; Zhang J; Wang B; Liu PN
J Neurosurg; 2023 Jun; 138(6):1680-1687. PubMed ID: 36272122
[TBL] [Abstract][Full Text] [Related]
13. Discovering Associations of Adverse Events with Pharmacotherapy in Patients with Non-Small Cell Lung Cancer Using Modified Apriori Algorithm.
Chen W; Yang J; Wang HL; Shi YF; Tang H; Li GH
Biomed Res Int; 2018; 2018():1245616. PubMed ID: 29850483
[TBL] [Abstract][Full Text] [Related]
14. Quantitative evaluation of the impact of relaxing eligibility criteria on the risk-benefit profile of drugs for lung cancer based on real-world data.
Huang H; Jia S; Wang X; Miao H; Fang H; He H; Wu D; Tang Y; Li N
Thorac Cancer; 2024 May; 15(14):1187-1194. PubMed ID: 38576119
[TBL] [Abstract][Full Text] [Related]
15. Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous nonsmall-cell lung cancer patients harboring wild-type EGFR (CTONG0806): a multicenter randomized trial.
Zhou Q; Cheng Y; Yang JJ; Zhao MF; Zhang L; Zhang XC; Chen ZH; Yan HH; Song Y; Chen JH; Feng WN; Xu CR; Wang Z; Chen HJ; Zhong WZ; Liu YP; Wu YL
Ann Oncol; 2014 Dec; 25(12):2385-2391. PubMed ID: 25281710
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of erlotinib in previously treated patients with advanced non-small cell lung cancer: analysis of the Chinese subpopulation in the TRUST study.
Huang Y; Zhang L; Shi Y; Ma S; Liao M; Bai C; Zhang Q; Wang C; Luo F; Yu S; Qin S; Zhi X; Zhou C
Jpn J Clin Oncol; 2015 Jun; 45(6):569-75. PubMed ID: 25855621
[TBL] [Abstract][Full Text] [Related]
17. Final overall survival results from a phase III, randomized, placebo-controlled, parallel-group study of gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804).
Zhao H; Fan Y; Ma S; Song X; Han B; Cheng Y; Huang C; Yang S; Liu X; Liu Y; Lu S; Wang J; Zhang S; Zhou C; Wang M; Zhang L;
J Thorac Oncol; 2015 Apr; 10(4):655-64. PubMed ID: 25546556
[TBL] [Abstract][Full Text] [Related]
18. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.
Yang JC; Wu YL; Schuler M; Sebastian M; Popat S; Yamamoto N; Zhou C; Hu CP; O'Byrne K; Feng J; Lu S; Huang Y; Geater SL; Lee KY; Tsai CM; Gorbunova V; Hirsh V; Bennouna J; Orlov S; Mok T; Boyer M; Su WC; Lee KH; Kato T; Massey D; Shahidi M; Zazulina V; Sequist LV
Lancet Oncol; 2015 Feb; 16(2):141-51. PubMed ID: 25589191
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of erlotinib in elderly patients in the phase IV POLARSTAR surveillance study of Japanese patients with non-small-cell lung cancer.
Yoshioka H; Komuta K; Imamura F; Kudoh S; Seki A; Fukuoka M
Lung Cancer; 2014 Nov; 86(2):201-6. PubMed ID: 25280386
[TBL] [Abstract][Full Text] [Related]
20. BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer.
Zhou C; Wu YL; Chen G; Liu X; Zhu Y; Lu S; Feng J; He J; Han B; Wang J; Jiang G; Hu C; Zhang H; Cheng G; Song X; Lu Y; Pan H; Zheng W; Yin AY
J Clin Oncol; 2015 Jul; 33(19):2197-204. PubMed ID: 26014294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
